<DOC>
	<DOCNO>NCT00448760</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , floxuridine , docetaxel , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well combination chemotherapy work treat patient previously untreated stage II stage III esophageal cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Previously Untreated Stage II Stage III Esophageal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether neoadjuvant chemotherapy comprise oxaliplatin , floxuridine , docetaxel , leucovorin calcium improve rate pathologic complete response patient previously untreated , resectable stage II III adenocarcinoma esophagus . Secondary - Determine progression-free overall survival patient treat regimen . - Determine clinical response rate ( complete response partial response ) patient treat regimen . - Evaluate thymidylate synthase ( TS ) , mRNA gene expression , TS activity , TS mRNA sequence , determine alter spot related drug resistance patient . - Evaluate potential genome-wide gene expression profile predict response therapy , recurrence , progression-free survival , overall survival , drug sensitivity resistance patient . - Define role 5 ' untranslated region ( 5'-UTR ) translation drug resistance patient . - Evaluate , bone marrow aspirate analysis flow cytometry , initial presence cancer cell marrow , clearance cell treatment regimen . - Evaluate safety regimen patient . - Assess quality life patient treatment regimen . OUTLINE : This nonrandomized , open-label study . Patients receive oxaliplatin IV 2 hour day 1 15 docetaxel IV 30 minute , floxuridine IV 24 hour , leucovorin calcium IV 24 hour day 1 , 8 , 15 . Treatment repeat every 4 week 2 course absence disease progression unacceptable toxicity . Patients undergo surgery completion chemotherapy . Patients achieve pathologic complete response ( pCR ) receive chemotherapy . Patients achieve pCR receive 2 course adjuvant chemotherapy ( regimen neoadjuvant chemotherapy ) begin 3 week surgery . Patients undergo blood tissue collection periodically correlative study . Samples analyze thymidylate synthase ( TS ) , mRNA gene expression , TS activity , TS mRNA sequence bone marrow aspirate , flow cytometry , quantitative reverse transcriptase-polymerase chain reaction . Quality life assess baseline , neoadjuvant chemotherapy , adjuvant therapy , first 3-month follow-up visit . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 34 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma esophagus meeting follow criterion : Stage II III disease Resectable disease Previously untreated disease No stage I ( mucosal ) stage IV ( metastatic ) disease PATIENT CHARACTERISTICS : WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine â‰¤ 2.0 mg/dL Bilirubin &lt; 2 time normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must central venous access No malignancy within past 5 year No concurrent medical psychiatric problem would preclude study treatment No contraindication paclitaxel PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy esophagus No oral cryotherapy ( e.g. , ice chip ) day 1 course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>